

Note : This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

June 25, 2024

To whom it may concern:

TOWA PHARMACEUTICAL CO., LTD.

Notice of Changes in Officers

Towa Pharmaceutical Co., Ltd. (hereinafter, the “Company”) is pleased to announce the following changes in directors as resolved at its Ordinary General Meeting of Shareholders and Board of Directors meeting held on June 25, 2024.

1. New executive structure (As of June 25)

(Changes are underlined and bolded.)

	<u>New position</u>	Current position	Name
Reappointed	(Unchanged)	President and Representative Director	Itsuro Yoshida
Reappointed	(Unchanged)	Director	Osamu Uchikawa
Newly appointed	<u>Director</u>	Operating Officer in charge of Corporate Strategy Division, Human Resources Division, Administration Division, Finance & Accounting Division, Sales and Marketing Division, Logistic Department and Production Division	Toshikazu Kokubun
Newly appointed	<u>Director</u>	Assistant to Corporate Strategy Division, in charge of Pharmaceutical CDMO Management Division, International Business Division, Business Development Unit and Digital Health Planning and Promotion Office	Masaaki Takeyasu
Newly appointed	<u>Outside Director</u>	Outside Director (Audit and Supervisory Committee Member)	Norikazu Eiki*
Newly appointed	<u>Director (Audit and Supervisory Committee Member)</u>	Director	Masao Tanaka
Reappointed	(Unchanged)	Outside Director (Audit and Supervisory Committee Member)	Kaori Oishi*
—	(Unchanged)	Outside Director (Audit and Supervisory Committee Member)	Kenryo Goto*
Newly appointed	<u>Outside Director (Audit and Supervisory Committee Member)</u>	—	Nobuki Ando*

* Outside Directors as prescribed in Article 2, Item 15 of the Companies Act

Itsuro Yoshida, Osamu Uchikawa, Toshikazu Kokubun, and Masaaki Takeyasu are responsible officers under the revised Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

End of Notice